Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes

Diabetes Care

Volumn 35, Issue 3, 2012, Pages 495-497

  Nichols, Gregory A ^a   Kimes, Teresa M ^a   Harp, Joyce B ^b   Kou, Tzuyung Doug ^b   Brodovicz, Kimberly G ^b  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; PIG INSULIN; SHORT ACTING INSULIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DOSE COMPARISON; DRUG USE; GLYCEMIC RESPONSE; GOAL ATTAINMENT; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROBABILITY; TREATMENT RESPONSE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 84859040764     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1171     Document Type: Article

References (8)

1. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement formultiple therapies (UKPDS 49). JAMA 1999;281:2005-2012 (Pubitemid 29254858)
2. Nichols GA, Gandra SR, Chiou CF, Anthony MS, Alexander-Bridges M, Brown JB. Successes and challenges of insulin therapy for type 2 diabetes in a managedcare setting. Curr Med Res Opin 2010;26:9-15
3. Nichols GA, Vupputuri S, Lau H. Medical care costs associated with progression of diabetic nephropathy. Diabetes Care 2011; 34:2374-2378
4. American Diabetes Association. Standards ofmedical care in diabetes: 2011. Diabetes Care 2011;34(Suppl. 1):S11-S61
5. Liebl A, Jones S, Benroubi M, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Curr Med Res Opin 2011;27:887-895
6. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357: 1716-1730 (Pubitemid 350005153)
7. Nichols GA, Conner C, Brown JB. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin 2010;26:2127-2135
8. Karter AJ, Moffet HH, Liu J, et al. Glycemic response tonewly initiated diabetes therapies. Am J Manag Care 2007;13:598-606 (Pubitemid 350106949)